SNRPA upregulation promotes mitochondrial function and drives CRPC aggressiveness

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Identifying novel molecular targets is critical for treating castration-resistant prostate cancer (CRPC).
• Small nuclear ribonucleoprotein polypeptide A (SNRPA), a U1 snRNP component, has an uncharacterized role in cancer.
• Elevated SNRPA expression correlates with prostate cancer aggressiveness and poor patient outcomes.

Purpose of the Study:

• To investigate the expression and functional significance of SNRPA in CRPC.
• To determine if SNRPA can be a viable therapeutic target for CRPC.

Main Methods:

• Bioinformatic analysis of patient data and single-cell RNA sequencing.
• In vitro studies involving SNRPA knockdown (shRNA) and knockout (CRISPR/Cas9) in CRPC cells.
• In vivo xenograft models to assess the therapeutic potential of SNRPA inhibition.

Main Results:

• SNRPA is overexpressed in CRPC tissues and cells, correlating with poor prognosis.
• SNRPA depletion reduces CRPC cell proliferation, migration, invasion, and induces apoptosis.
• SNRPA affects mitochondrial function, including Complex I activity, ATP production, and redox balance.
• SNRPA overexpression enhances CRPC aggressiveness and mitochondrial activity.
• In vivo, SNRPA knockdown inhibits tumor growth and alters tumor cell metabolism and redox state.

Conclusions:

• SNRPA is a key driver of CRPC progression by influencing cellular metabolism and proliferation.
• SNRPA represents a promising molecular target for developing novel CRPC therapies.